Reproductive Hormones and Proteins Tests - In Vitro Diagnostics Market Analysis and Forecast Model

Reproductive Hormones and Proteins Tests - In Vitro Diagnostics Market Analysis and Forecast Model

  • July 2017 •
  • Report ID: 5399518 •
  • Format: PDF
Reproductive Hormones and Proteins Tests - In Vitro Diagnostics Market Analysis and Forecast Model

Reproductive Hormones and Proteins Tests - In Vitro Diagnostics Market Analysis and Forecast Model is built to better visualize quantitative market trends of Reproductive Hormones and Proteins Tests within the In Vitro Diagnostics market.

The color-coded and fully-sourced models are equipped with epidemiology based indications with procedure volumes.To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share analysis.

Moreover, analyst comments with qualitative insight offer context for quantitative data.

Reproductive hormones and proteins assist in the control and regulation of physiological processes including metabolism, reproduction, and growth and development. They are secreted either from endocrine glands or from organs with secondary endocrine function (such as the pancreas, liver, kidneys, and gonads) and affect the health and behavior of both males and females.

The tests covered in this model are performed to detect, measure, and monitor the presence of specific reproductive hormones and proteins in a patient’s sample. Tests included under this segment are employed for early pregnancy diagnosis and pregnancy-related problems, as well as to examine the reasons for infertility, polycystic ovaries, and other menstrual-related complications.

15 hormone and protein tests are included in this model: the Beta Human Chorionic Gonadotropic (hCG) test, Free Beta hCG test, Pregnancy Associated Plasma Protein A (PAPP-A) test, Total hCG test, Unconjugated Estriol (uE3) test, Alpha Fetoprotein (AFP) test, Inhibin A test, Anti-Mullerian Hormone (AMH) test, Estradiol test, Progesterone test, Follicle Stimulating Hormone (FSH) test, Luteinizing Hormone (LH) test, Testosterone test, Dehydroepiandrosterone Sulfate (DHEAS) test, and Prolactin test.

Each of the covered 39 country’s market models are further segmented to provide granularity and pertinent data for respective market.

Key Inclusions of these market models are -
- Currently marketed Reproductive Hormones and Proteins Tests and evolving competitive landscape.
- Insightful review of the key industry trends.
- Annualized total Reproductive Hormones and Proteins Tests market revenue by segment and market outlooks from 2005-2024.
- Granular data on total procedures, units, average selling prices and market values by segment.

Robust methodologies and sources enable these market models to provide extensive and accurate overviews of markets. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders.

Built with help of thousands of interviews with demand side participants, majority of them are physicians, surgeons, and specialists within their therapeutic areas. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, Chile

This Market Model gives important, expert insight you won’t find in any other source.

The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
- CMO executives who must have a deep understanding of the marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy
The model will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Reproductive Hormones and Proteins Tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Reproductive Hormones and Proteins Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific Reproductive Hormones and Proteins Tests market from 2005-2024
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.